This article presents the structure of tirzepatide, its mechanism of action, an overview of
clinical trial results, and its safety assessment. Clinical trial results have shown a very
beneficial effect of tirzepatide on glycemic control and bodyweight reduction. In all
performed phase III studies, tirzepatide was more effective than any other drug used in any
reference group (including semaglutide). Double agonism of incretin hormones seems to be
a promising therapeutic concept.